nAbCyte™ CDx: One-time treatment. Zero room for error.
3 October 2024
Break through in partnership
Learn how Labcorp developed nAbCyte™, the first CDx for a cell-based gene therapy, providing greater access to a potential cure for patients with hemophilia B.
Latest content on gene therapy and companion diagnostics
Press release
FDA approves first companion diagnostic for use with Pfizer's newly approved gene therapy to treat patients with hemophilia B.
nAbCyteTM hemophilia B
Testing program provided by Labcorp
Cell and gene therapy
From research and development of cell and gene therapy products to next-generation sequencing testing, our scientists are finding answers.
Companion diagnostics
Parallel development of a companion diagnostic with a novel therapeutic is challenging—but the value of proving your treatment’s efficacy with targeted biomarkers has never been greater.